



5th World Congress on Controversies in Breast Cancer

When is Less More?

hosted by



University of California
San Francisco

September 4-6, 2019
San Francisco, CA, USA



www.cobrca.org
coBrca@congressmed.com
industry@congressmed.com

Welcome to San Francisco

The 5th World Congress on Controversies in Breast Cancer (CoBrCa) will take place in San Francisco, September 4-6, 2019. The 5th edition of the congress will continue to explore and address controversial issues in breast cancer management. It will also include and will include strong Surgical and Radiology components that should be of interest to all Breast surgeons.

Judy Boughey from Mayo, Chip Cody from Memorial, Alastair Thompson and Abigail Caudle from Houston will join Laura Esserman, Michael Alvarado and others from San Francisco to form the core of the surgical faculty, with Christiane Kuhl, Ritse Mann, Julia Camps-Herrero and Allison Rose forming a strong international Breast radiology faculty. They will be joining a stellar international faculty including medical oncologists, radiation oncologists and others to present a very thought-provoking conference.

When the idea of a "Controversies in Breast Cancer" congress was first discussed, many thought that there was no need for another congress. Its format of specifically and explicitly addressing clinically relevant controversial issues has made it very successful, with prior meetings held in Melbourne, Barcelona, Tokyo, Melbourne and now San Francisco. See the full [program](#) and remember that [early registration](#) closes on July 10.

Congress Co-Chairpersons

Laura Esserman, *San Francisco, USA*

Alastair Thompson, *Houston, USA*

Angela DeMichele, *Philadelphia, USA*

Javier Cortes, *Madrid, Spain*

Richard De Boer, *Melbourne, Australia*

Bruce Mann, *Melbourne, Australia*



5th World Congress
on **Controversies** in
Breast Cancer
When is Less More?

Follow us on:



Debating the controversies: When is less more?

Program Highlights – Surgery Debates

Plenary Session 1: Neoadjuvant therapy

Debate: **A path CR allows de-escalation of further therapies**

Yes: **Javier Cortes**, *Spain*

No: **Mark D. Pegram**, *USA*

Discussion

Plenary Session 3: Genetics

Debate: **That most patients with breast cancer should be panel tested**

Yes: **Laura Van t'veer**, *USA*

No: **Allison W. Kurian**, *USA*

Discussion

Debate: **That all gene carriers with early breast cancer should have a bilateral mastectomy**

Yes: **Rita Mukhtar**, *USA*

No: **Ava Kwong**, *Hong Kong*

Discussion

Parallel Session 5: Imaging / Screening

MRI screening in women without hereditary risk

Ritse Mann, *The Netherlands*

The implications of a move to MRI screening

Allison Rose, *Australia*

Debate: **That women with low risk for breast cancer should only be screened every 3 years**

Yes: **Andrea LaCroix**, *USA*

No: **Heather Greenwood**, *USA*

Parallel Session 7: DCIS

Debate: **That most DCIS should not be a target for screening**

Yes: **Laura Esserman**, *USA*

No: **Bruce Mann**, *Australia*

Discussion

Debate: **Most patients with DCIS should not have radiotherapy after Breast Conserving Surgery**

Yes: **Alastair Thompson**, *USA*

No: **Thomas A. Buchholz**, *USA*

Discussion

Parallel Session 9: Issues in locoregional management

Debate: **Despite ACOSOG Z11 and AMAROS, there is still a role for axillary surgery in patients with a positive sentinel node**

Yes: **Abigail Caudle**, *USA*

No: **Hiram S. Cody**, *USA*

Discussion

Debate: **That regional nodal radiation should be routine for patients with axillary metastasis**

Yes: **Thomas A. Buchholz**, *USA*

No: **Catherine Park**, *USA*

Discussion

Parallel Session 16: Reconstruction

Debate: **That one surgeon is better than two**

Yes: **Amit Agrawal**, *UK*

No: **Mark V. Schaverien**, *USA*

Discussion

Debate: **That patients requiring postmastectomy radiotherapy should not undergo immediate reconstruction**

Yes: **Alastair Thompson**, *USA*

No: **Jiong Wu**, *China*

Discussion

[View the full scientific program](#)